Metoprolol Tartrate Tablets

This drug belongs to Class 2A, i.e., beta 1-receptor blockers without partial agonist activity (cardioselective beta 1-receptor blockers). It has a selective blocking effect on beta 1-receptors, no PAA (partial agonist activity), and no membrane stabilizing effect. Its effect on blocking beta 1-receptors is approximately equal to that of propranolol (PP), and its selectivity for beta 1-receptors is slightly inferior to that of atenolol. Metoprolol's effects on the heart, such as slowing heart rate, inhibiting cardiac contractility, reducing automaticity, and delaying atrioventricular conduction time, are similar to those of propranolol and atenolol (AT). Its effect on reducing elevated blood pressure and heart rate during exercise testing is also similar to that of PP and AT. Its contraction effect on vascular and bronchial smooth muscle is weaker than that of PP, so its effect on the respiratory tract is also smaller, but still stronger than that of AT. Metoprolol can also reduce plasma renin activity.

The main ingredient of this product is metoprolol tartrate

This product is white tablets.

It is used to treat hypertension, angina pectoris, myocardial infarction, hypertrophic cardiomyopathy, aortic dissection, arrhythmia, hyperthyroidism, cardiac neurosis, etc. In recent years, it is also used to treat heart failure, and it should be used under the guidance of an experienced physician.

For the treatment of hypertension, 100-200 mg/time, twice a day, should be used immediately after hemodynamic stabilization. Acute myocardial infarction advocates early use, i.e., within the first few hours, because immediate use can reduce the infarction range and reduce the short-term (15-day) mortality rate in patients who have not undergone thrombolysis (this effect appears 24 hours after medication). It can reduce the reinfarction rate and re-ischemia rate in patients who have undergone thrombolysis, and can also reduce the mortality rate if the medication is used within 2 hours. General usage: Metoprolol can be injected intravenously at 2.5-5 mg/time (within 2 minutes), once every 5 minutes, for a total of 3 times of 10-15 mg. After 15 minutes, start taking 25-50 mg orally, once every 6-12 hours, for a total of 24-48 hours, and then take 50-100 mg orally, twice a day.

1. Cardiovascular system: slowed heart rate, conduction block, lowered blood pressure, worsening heart failure, cold limbs or untouchable pulse due to peripheral vascular spasm, Raynaud's phenomenon. 2. Because of its fat solubility and easy penetration into the central nervous system, this system has more adverse reactions. Fatigue and dizziness account for 10%, depression accounts for 5%, and others include headache, dreaminess, insomnia, etc. Hallucinations are occasionally seen. 3. Digestive system: nausea, stomachache, constipation account for 1%, diarrhea accounts for 5%, but it is not serious and rarely affects medication. 4. Others: shortness of breath, joint pain, itching, retroperitoneal fibrosis, deafness, eye pain, etc.

1. It is contraindicated for use in patients with hypotension, significant bradycardia (heart rate 45/min), cardiogenic shock, severe or acute heart failure, poor peripheral circulation perfusion, second-degree or third-degree atrioventricular block, sick sinus syndrome, and severe peripheral vascular disease; 2. It should not be used during pregnancy or delivery.

Precautions for children: There is limited experience with the use of this product in children. Precautions for pregnancy and lactation: It should not be used during pregnancy or delivery. Precautions for the elderly: The pharmacokinetics of the elderly are not significantly different from those of young people, so the dosage of elderly patients does not need to be adjusted.

Patients should be closely monitored if they are also taking sympathetic ganglion blockers, other beta-blockers (e.g., current limiters), or monoamine oxidase (MAO) inhibitors. If discontinuation of co-administration with clonidine is planned, beta-blockers should be withdrawn a few days before clonidine withdrawal. Concomitant use of metoprolol with verapamil and dihydropyridine calcium antagonists may increase negative inotropic and chronotropic effects. Verapamil-type calcium antagonists should not be given intravenously in patients taking beta-blockers. Beta-blockers increase the negative inotropic and negative chronotropic effects of antiarrhythmic drugs (quinidines and amiodarone). Patients receiving beta-blockers. Inhalation anesthesia increases cardiodepressant effects. Enzyme-inducing and enzyme-inhibiting substances affect metoprolol plasma levels. Rifampin decreases metoprolol plasma concentrations. Cimetidine, ethanol, hydralazine, and selective serotonin reuptake inhibitors (SSRIs), such as paroxetine, fluoxetine, and sertraline, increase metoprolol plasma concentrations. Pre-administration of nabdomyosarcoma may also increase metoprolol plasma concentrations. Co-administration with indomethacin or other prostaglandin synthase inhibitors reduces the antihypertensive effect of beta-blockers. In some cases, patients taking beta-blockers use epinephrine, and cardioselective beta-blockers have much less effect on blood pressure control than non-selective beta-blockers. The dose of oral hypoglycemic agents must be adjusted in patients receiving beta-blocker therapy.

Keep away from light and store in sealed container.

25mg

36 months

Hunan Weite Pharmaceutical Co., Ltd.

• Founded in:

  2003-03-31

• Address:

  No. 97, Kangping Road, Liuyang Economic and Technological Development Zone

• Tax NO.:

  914301817406413726

• Registered Funds:

  10 million yuan

• Website:

  Log in to view

• Email:

  Log in to view